Gothenburg, Sweden – [November 6, 2026] – MucoLife Therapeutics AB has been granted SEK 1 million by Vinnova, Sweden’s innovation agency, in the call “Support to small and medium-sized companies for the use of life science infrastructure.” The funding supports establishing a scalable manufacturing process for MLT-001, the company’s first-in-class inhaled peptide designed to dissolve airway mucus plugs in chronic obstructive pulmonary disease (COPD).
Mucus plugging is present in more than half of patients with moderate-to-severe COPD, and no approved therapy targets it directly. Mucus obstruction is a relevant disease feature associated with poor outcomes, including reduced lung function, more exacerbations and increased mortality, and they can be targeted for the benefit of patients. MucoLife’s work has shown that the synthesis of MLT-001 is scalable, and the grant will be used to develop the process of scaled-up manufacturing.
The development will be carried out in close collaboration with a contract development and manufacturing organization (CDMO) partner and aims to establish a process that reaches a suitable level of purity at a documented yield. The project will also deliver a transferable process description and control strategy for later Good Manufacturing Practice (GMP) manufacture.
“Manufacturing is the step that turns a promising molecule into a medicine,” says Thaher Pelaseyed, CEO of MucoLife. “With Vinnova’s support, we can build the purification process for MLT-001 and move closer to clinical trials.”
About MucoLife Therapeutics
MucoLife is a Gothenburg-based biopharmaceutical company developing MLT-001, a first-in-class inhaled mucus modulator for COPD and other muco-obstructive lung diseases. MLT-001 is an investigational, preclinical compound.
Press contact, MucoLife Therapeutics:
Thaher Pelaseyed, PhD
CEO
MucoLife Therapeutics AB
tpelaseyed@mucolife.com
+46 733 79 43 47
This press release contains forward-looking statements based on current expectations and assumptions. Actual results may differ materially. Preclinical results do not guarantee clinical outcomes.